688428 诺诚健华
已收盘 07-13 15:00:01
资讯
新帖
简况
每周股票复盘：诺诚健华（688428）科创板股份归属上市
证券之星 · 07-12 02:32
每周股票复盘：诺诚健华（688428）科创板股份归属上市
诺诚健华（688428）披露2023年科创板限制性股票激励计划归属结果暨股份上市公告，7月10日股价上涨2.34%
证券之星 · 07-10 22:29
诺诚健华（688428）披露2023年科创板限制性股票激励计划归属结果暨股份上市公告，7月10日股价上涨2.34%
港股创新药概念股盘中拉升，荣昌生物、诺诚健华涨超5%
老虎资讯综合 · 07-10
港股创新药概念股盘中拉升，荣昌生物、诺诚健华涨超5%
诺诚健华：截止到2026年6月30日公司A股股东户数约为2万户
证券之星 · 07-07
诺诚健华：截止到2026年6月30日公司A股股东户数约为2万户
诺诚健华盘中涨超9% 自研靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药
新浪港股 · 07-06
诺诚健华盘中涨超9% 自研靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药
诺诚健华宣布新型Cdh17靶向ADC药物ICP-B208中国临床试验首例患者完成给药
美股速递 · 07-06
诺诚健华宣布新型Cdh17靶向ADC药物ICP-B208中国临床试验首例患者完成给药
诺诚健华（688428）披露根据2023年股权激励计划授出受限制股份单位，7月1日股价上涨3.86%
证券之星 · 07-01
诺诚健华（688428）披露根据2023年股权激励计划授出受限制股份单位，7月1日股价上涨3.86%
半导体设备板块短线走低，恒运昌跌超13%
智通财经 · 07-01
半导体设备板块短线走低，恒运昌跌超13%
6月29日诺诚健华涨13.08%，富国精准医疗混合A基金重仓该股
证券之星 · 06-29
6月29日诺诚健华涨13.08%，富国精准医疗混合A基金重仓该股
诺诚健华涨13.08%，长城国瑞证券二个月前给出“买入”评级
证券之星 · 06-29
诺诚健华涨13.08%，长城国瑞证券二个月前给出“买入”评级
诺诚健华(09969)：根据2024年人民币股股份激励计划发行241.83万股新人民币股份
智通财经 · 06-26
诺诚健华(09969)：根据2024年人民币股股份激励计划发行241.83万股新人民币股份
诺诚健华：多位股东计划减持公司股份
南方财经网 · 06-24
诺诚健华：多位股东计划减持公司股份
诺诚健华（688428）披露2024年科创板限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市，6月23日股价上涨2.25%
证券之星 · 06-23
诺诚健华（688428）披露2024年科创板限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市，6月23日股价上涨2.25%
6月18日诺诚健华涨6.90%，富国精准医疗混合A基金重仓该股
证券之星 · 06-18
6月18日诺诚健华涨6.90%，富国精准医疗混合A基金重仓该股
港股异动 | 诺诚健华(09969)盘中涨超5% 坦昔妥单抗联合疗法治疗初治DLBCLⅢ期研究于EHA年会发布
智通财经 · 06-18
港股异动 | 诺诚健华(09969)盘中涨超5% 坦昔妥单抗联合疗法治疗初治DLBCLⅢ期研究于EHA年会发布
诺诚健华（688428）披露2023年激励计划首次授予部分第三个归属期符合归属条件公告，6月16日股价下跌2.42%
证券之星 · 06-16
诺诚健华（688428）披露2023年激励计划首次授予部分第三个归属期符合归属条件公告，6月16日股价下跌2.42%
诺诚健华(09969)授出800万股限制性股票
智通财经 · 06-16
诺诚健华(09969)授出800万股限制性股票
诺诚健华涨10.87%，长城国瑞证券二个月前给出“买入”评级
证券之星 · 06-12
诺诚健华涨10.87%，长城国瑞证券二个月前给出“买入”评级
诺诚健华：公司目前不存在应披露而未披露的主要资产出售或整体出售计划
证券之星 · 06-11
诺诚健华：公司目前不存在应披露而未披露的主要资产出售或整体出售计划
诺诚健华：截止到2026年5月29日公司A股股东户数约为2万户
证券之星 · 06-11
诺诚健华：截止到2026年5月29日公司A股股东户数约为2万户
公司概况
公司名称：
诺诚健华医药有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼。
发行价格：
11.03
{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":29.18,"timestamp":1783926001000,"preClose":29.78,"halted":0,"volume":12145125,"delay":0,"changeRate":-0.0201,"floatShares":271000000,"shares":1769000000,"eps":0.4129,"marketStatus":"已收盘","change":-0.6,"latestTime":"07-13 15:00:01","open":29.5,"high":30.3,"low":29,"amount":360000000,"amplitude":0.0437,"askPrice":29.2,"askSize":10,"bidPrice":29.18,"bidSize":89,"shortable":0,"etf":0,"ttmEps":0.4129,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783992600000},"marketStatusCode":5,"adr":0,"adjPreClose":29.78,"symbolType":"stock_kcb","openAndCloseTimeList":[[1783906200000,1783913400000],[1783918800000,1783926000000]],"highLimit":32.76,"lowLimit":26.8,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1769107002,"isCdr":false,"pbRate":7.03,"roa":"--","peRate":70.670865,"roe":"1.4%","epsLYR":0.38,"committee":0.436548,"marketValue":51623000000,"turnoverRate":0.0449,"status":1,"afterMarket":{"amount":0,"volume":0,"close":29.18,"buyVolume":1000,"sellVolume":0,"time":1783928037746,"indexStatus":"已收盘 07-13 15:30:00","preClose":29.78},"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":14.18,"timestamp":1783930121009,"preClose":13.98,"halted":0,"volume":13372000,"delay":0,"premium":"-57.97"},"floatMarketCap":7901000000},"requestUrl":"/m/hq/s/688428/wiki","defaultTab":"wiki","newsList":[{"id":"2650815490","title":"每周股票复盘：诺诚健华（688428）科创板股份归属上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2650815490","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650815490?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:32","pubTimestamp":1783794729,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，诺诚健华报收于29.78元，较上周的30.18元下跌1.33%。本周关注点来自公司公告汇总：诺诚健华完成2023年科创板限制性股票激励计划部分归属，新增股份2,044,750股于2026年7月15日上市。诺诚健华医药有限公司完成2023年科创板限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属期的股份登记工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","688428","BK1574","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650010135","title":"诺诚健华（688428）披露2023年科创板限制性股票激励计划归属结果暨股份上市公告，7月10日股价上涨2.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650010135","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650010135?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:29","pubTimestamp":1783693755,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，诺诚健华报收于29.78元，较前一交易日上涨2.34%，最新总市值为526.23亿元。公告显示，公司已完成2023年科创板限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属期的股份登记工作。本次归属合计134人，归属股票数量为2,044,750股，来源为公司向激励对象定向发行人民币普通股股票。上市流通日为2026年7月15日。安永华明会计师事务所已完成验资，公司已收到激励对象缴纳的合计人民币14,211,012.50元出资款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","09969","688428","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180945737","title":"港股创新药概念股盘中拉升，荣昌生物、诺诚健华涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180945737","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180945737?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:01","pubTimestamp":1783648919,"startTime":"0","endTime":"0","summary":"7月10日，港股创新药概念股盘中拉升，$荣昌生物(09995)$、$诺诚健华(09969)$涨超5%，$药明康德(02359)$、$药明生物(02269)$、$亚盛医药(06855)$、$乐普生物(02157)$涨超4%，$恒瑞医药(01276)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","159992","688428","688331","BK1161","IBBQ","LU2488822045.USD","06978","LU1064131003.USD","09969","BK0239","LU2148510915.USD","MEDX","VXUS","BK1583","BK4585","LU1969619763.USD","LU1064130708.USD","09995","KCAI","BK4588","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649985891","title":"诺诚健华：截止到2026年6月30日公司A股股东户数约为2万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2649985891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649985891?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:06","pubTimestamp":1783415169,"startTime":"0","endTime":"0","summary":"证券之星消息，诺诚健华(688428)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司截止6月30日的股东人数诺诚健华回复：尊敬的投资者，您好！截止到2026年6月30日公司A股股东户数约为2万户。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700028459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399300","09969","BK0239","BK1574","BK1161","159982","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649461757","title":"诺诚健华盘中涨超9% 自研靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2649461757","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649461757?lang=zh_cn&edition=full","pubTime":"2026-07-06 09:52","pubTimestamp":1783302720,"startTime":"0","endTime":"0","summary":" 诺诚健华盘中涨超9%，截至发稿，股价上涨6.42%，现报13.92港元，成交额5426.90万港元。 7月6日，据诺诚健华官微消息，公司宣布自主研发的靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药。基于诺诚健华自主研发的ADC技术平台，ICP-208由人源化抗CDH17抗体通过蛋白酶可裂解连接子与公司自主开发的强效有效载荷偶联而成，可精准靶向肿瘤细胞，同时最大限度减少脱靶效应。目前，全球尚无CDH17靶向ADC新药上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-06/doc-inifvqsf1795989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK4231","ADC","MEDX","BK1161","IBBQ","688428","BK4080","06978","BK0239","159992","09969","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140314939","title":"诺诚健华宣布新型Cdh17靶向ADC药物ICP-B208中国临床试验首例患者完成给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1140314939","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140314939?lang=zh_cn&edition=full","pubTime":"2026-07-06 09:01","pubTimestamp":1783299689,"startTime":"0","endTime":"0","summary":"诺诚健华宣布，其新型Cdh17靶向抗体偶联药物ICP-B208在中国的临床试验中，已完成对首例患者的给药。这一进展标志着该创新疗法在中国正式进入临床研究阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648549090","title":"诺诚健华（688428）披露根据2023年股权激励计划授出受限制股份单位，7月1日股价上涨3.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648549090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648549090?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:23","pubTimestamp":1782915793,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，诺诚健华报收于29.57元，较前一交易日上涨3.86%，最新总市值为522.52亿元。该股当日开盘28.38元，最高30.05元，最低27.06元，成交额达5.37亿元，换手率为6.89%。近日，诺诚健华医药有限公司披露公告显示，公司于2026年6月30日根据2023年股权激励计划向八名承授人授出1,910,000份受限制股份单位，占公司已发行股份总数约0.11%。1,480,000份受限制股份单位将在一至四年内分四期等额归属，其余430,000份以达成公司及个人层面业绩目标为归属条件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK0239","BK1574","BK1161","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648786597","title":"半导体设备板块短线走低，恒运昌跌超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648786597","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648786597?lang=zh_cn&edition=full","pubTime":"2026-07-01 14:17","pubTimestamp":1782886664,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["688082","BK0251","688409","688428","BK0239","BK0259","688037","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647832239","title":"6月29日诺诚健华涨13.08%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647832239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647832239?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:39","pubTimestamp":1782722398,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日诺诚健华涨13.08%，收盘报28.61元，换手率8.5%，成交量23.01万手，成交额6.36亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共28家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为31.86亿元，最新净值2.9889，较上一交易日下跌3.51%，近一年下跌3.06%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688428","BK0239","09969","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647223153","title":"诺诚健华涨13.08%，长城国瑞证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2647223153","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647223153?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:39","pubTimestamp":1782722392,"startTime":"0","endTime":"0","summary":"今日诺诚健华涨13.08%，收盘报28.61元。2026年3月31日，长城国瑞证券研究员胡晨曦,魏钰琪发布了对诺诚健华的研报《盈利拐点初现，商业化放量与技术授权双轮驱动》，该研报对诺诚健华给出“买入”评级。因此，我们维持其“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为国海证券的孔维崎、周小刚。诺诚健华个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646840353","title":"诺诚健华(09969)：根据2024年人民币股股份激励计划发行241.83万股新人民币股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2646840353","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646840353?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:16","pubTimestamp":1782465406,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，于2026年6月26日，根据2024年人民币股股份激励计划首次授予部分第一个归属期的归属结果向2名董事发行79.5万股新人民币股份(于2024年12月17日采纳)。于2026年6月26日，根据2024年人民币股股份激励计划首次授予部分第一个归属期的归属结果向2名高级管理人员发行20万股新人民币股份(于2024年12月17日采纳)。于2026年6月26日，根据2024年人民币股股份激励计划首次授予部分第一个归属期的归属结果向70名激励对象发行142.23万股新人民币股份(于2024年12月17日采纳)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","688428","UCmain","09969","CYB","CNHmain","MCNHmain","MUCmain","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645902892","title":"诺诚健华：多位股东计划减持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2645902892","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645902892?lang=zh_cn&edition=full","pubTime":"2026-06-24 18:54","pubTimestamp":1782298440,"startTime":"0","endTime":"0","summary":"诺诚健华：多位股东计划减持公司股份","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606243781555560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","688428","BK1161","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645383250","title":"诺诚健华（688428）披露2024年科创板限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市，6月23日股价上涨2.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645383250","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645383250?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:14","pubTimestamp":1782224091,"startTime":"0","endTime":"0","summary":"近日，诺诚健华医药有限公司发布《关于2024年科创板限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市的公告》。公告显示，公司完成2024年科创板限制性股票激励计划首次授予部分第一个归属期的股份登记，本次归属股票数量为2,418,300股，来源为公司向激励对象定向发行人民币普通股，归属人数为74人，其中包含董事、高级管理人员及核心技术人等。本次归属新增股份已于2026年6月22日完成登记，上市流通日期为2026年6月26日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428","BK1161","BK1574","BK0239","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644706351","title":"6月18日诺诚健华涨6.90%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644706351","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644706351?lang=zh_cn&edition=full","pubTime":"2026-06-18 16:36","pubTimestamp":1781771817,"startTime":"0","endTime":"0","summary":"证券之星消息，6月18日诺诚健华涨6.90%，收盘报23.86元，换手率5.17%，成交量13.88万手，成交额3.26亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共28家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为31.86亿元，最新净值2.785，较上一交易日下跌1.15%，近一年下跌11.13%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800028753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688428","BK1161","09969","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644762357","title":"港股异动 | 诺诚健华(09969)盘中涨超5% 坦昔妥单抗联合疗法治疗初治DLBCLⅢ期研究于EHA年会发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2644762357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644762357?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:55","pubTimestamp":1781751327,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华盘中涨超5%，截至发稿，涨3.29%，报10.69港元，成交额4304.89万港元。消息面上，6月18日，据诺诚健华官微消息，公司宣布，在2026欧洲血液学协会年会最高级别的全体大会上，坦昔妥单抗联合疗法全球III期frontMIND研究结果以口头报告形式重磅发布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","BK4585","BK1161","VXUS","BK4588","09969","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643676393","title":"诺诚健华（688428）披露2023年激励计划首次授予部分第三个归属期符合归属条件公告，6月16日股价下跌2.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643676393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643676393?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:20","pubTimestamp":1781619621,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，诺诚健华报收于22.56元，较前一交易日下跌2.42%，最新总市值为398.1亿元。近日，诺诚健华医药有限公司发布《关于2023年科创板限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属期符合归属条件的公告》。公告显示，本次拟归属限制性股票数量为2,044,750股，其中首次授予部分1,641,500股，预留授予部分403,250股，股票来源为公司向激励对象定向发行人民币普通股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600044148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688428","09969","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643547657","title":"诺诚健华(09969)授出800万股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2643547657","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643547657?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:59","pubTimestamp":1781611192,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，于今日收市及股东周年大会结束后，公司已根据2026年人民币股份激励计划作出首次授予，向100名激励对象授予800万股限制性股票，占公司于本公告日期已发行股份总数约0.45%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1574","09969","688428","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642972265","title":"诺诚健华涨10.87%，长城国瑞证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2642972265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642972265?lang=zh_cn&edition=full","pubTime":"2026-06-12 16:29","pubTimestamp":1781252989,"startTime":"0","endTime":"0","summary":"今日诺诚健华涨10.87%，收盘报23.45元。2026年3月31日，长城国瑞证券研究员胡晨曦,魏钰琪发布了对诺诚健华的研报《盈利拐点初现，商业化放量与技术授权双轮驱动》，该研报对诺诚健华给出“买入”评级。因此，我们维持其“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为国海证券的孔维崎、周小刚。诺诚健华个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200025395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642288112","title":"诺诚健华：公司目前不存在应披露而未披露的主要资产出售或整体出售计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2642288112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642288112?lang=zh_cn&edition=full","pubTime":"2026-06-11 17:27","pubTimestamp":1781170045,"startTime":"0","endTime":"0","summary":"证券之星消息，诺诚健华(688428)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，面对公司目前的股价市值和账面的现金流余额，是否有外资药企比如 艾伯维，礼来对公司发出邀约收购？公司有无出售计划？诺诚健华回复：尊敬的投资者，您好！公司目前不存在应披露而未披露的主要资产出售或整体出售计划。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100027698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688428","BK0239","09969","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642288612","title":"诺诚健华：截止到2026年5月29日公司A股股东户数约为2万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2642288612","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642288612?lang=zh_cn&edition=full","pubTime":"2026-06-11 17:18","pubTimestamp":1781169486,"startTime":"0","endTime":"0","summary":"证券之星消息，诺诚健华(688428)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司截止5月31日的股东人数诺诚健华回复：尊敬的投资者，您好！截止到2026年5月29日公司A股股东户数约为2万户。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100027229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399300","BK0239","BK1161","159982","BK1574","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783948090497,"stockEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":0.4188},{"period":"3month","weight":0.0308},{"period":"6month","weight":0.3195},{"period":"1year","weight":0.1498},{"period":"ytd","weight":0.4513}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":0.0007},{"period":"3month","weight":0.0025},{"period":"6month","weight":-0.0302},{"period":"1year","weight":0.1386},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20000人(较上一季度增加0.00%)","perCapita":"13641股","listingDate":"2022-09-21","address":"Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands","registeredCapital":"0万元","survey":" 诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}